Alphatec Reports Breakeven Q1 Results Amid Market Optimism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 19 2025
0mins
Alphatec Holdings Inc's stock fell 31.57% as it crossed below the 5-day SMA, reflecting investor concerns despite the company's reported breakeven non-GAAP results for Q1 2026.
The company achieved breakeven results, indicating a successful transition from previous losses, but the market's cautious optimism suggests that investors are still wary of future growth potential. Additionally, Alphatec's revenue of $192 million for Q1, a 14% year-over-year increase, fell short of expectations primarily due to underperformance in EOS sales, which has led to a lowered outlook for the year. This mixed performance has contributed to the stock's significant decline.
Despite the challenges, Alphatec's surgical revenue growth indicates strong demand in the medical device sector. However, the company's inability to meet analyst expectations has raised concerns about its future performance, leading to increased volatility in its stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATEC
Wall Street analysts forecast ATEC stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 9.330
Low
20.00
Averages
24.33
High
28.00
Current: 9.330
Low
20.00
Averages
24.33
High
28.00
About ATEC
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alphatec Holdings Under Investigation for Investor Losses
- Revenue Decline: Alphatec Holdings reported a $3 million year-over-year decline in EOS revenue for Q1 2026, as system deliveries fell short of the previous year's figures, indicating increased pressure in market competition.
- Revised Revenue Guidance: The company lowered its 2026 EOS revenue forecast from approximately $85 million to $77 million, reflecting management's cautious outlook which may undermine investor confidence moving forward.
- Execution Flaw: CEO Patrick Miles identified installation timing as a challenge this quarter and labeled the unfulfilled unit commitments as an 'execution flaw,' which could negatively impact the company's market reputation and customer trust.
- Significant Stock Drop: Following these disclosures, Alphatec's stock price plummeted by approximately 32%, reflecting investor concerns about the company's future performance and potentially prompting more investors to seek legal remedies for their losses.
See More
U.S. Medical Devices ETF Underperforms
- ETF Decline: The iShares U.S. Medical Devices ETF fell approximately 2.4% in Tuesday afternoon trading, indicating overall weakness in the sector that may undermine investor confidence in medical devices.
- Weak Individual Stocks: Within the ETF, shares of Enovis dropped about 11.9%, while Alphatec Holdings fell by approximately 8.1%, with these significant declines likely negatively impacting the ETF's overall performance.
- Market Reaction Analysis: The poor performance of the medical device sector may reflect market concerns regarding the industry's future growth potential, particularly amid increasing economic uncertainty, prompting investors to reassess their portfolios.
- Investor Sentiment Shift: As the medical devices ETF underperforms, investors may shift towards stronger-performing ETFs, leading to capital outflows from the medical device sector and further exacerbating downward pressure on the industry.
See More
Alphatec Under Investigation as Shares Plunge 31.7%
- Investigation Launched: The Schall Law Firm has announced an investigation into Alphatec Holdings, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Disappointing Earnings: Alphatec's Q1 2026 financial results, released on May 5, revealed that revenue fell short of market expectations, with lower deliveries compared to the prior year, indicating operational challenges within the company.
- Revenue Outlook Downgraded: The company admitted to failing to fulfill committed unit quantities, leading to a lowered full-year 2026 revenue outlook, raising concerns about its future performance and exacerbating investor anxiety.
- Stock Price Volatility: Following the disappointing earnings and bleak outlook, Alphatec's shares plummeted by 31.7% on May 6, 2026, reflecting the market's strong reaction to the company's financial health, which could impact its ability to raise capital and investor confidence.
See More
Investment Analysis of Healthcare Device Players
- Alphatec Growth Momentum: Alphatec's revenue for FY 2025 reached approximately $764.2 million, reflecting a 25% increase, despite a net loss of about $143.4 million; however, its net margin improved from -26.5% to -18.8%, indicating growing market acceptance in spine surgery.
- Inspire's Profitability Improvement: Inspire Medical Systems achieved revenue of around $912 million in FY 2025, a 13.6% increase, and successfully transitioned to profitability with a net income of approximately $145.4 million, raising its net margin from 6.7% to 15.9%, solidifying its leadership in advanced respiratory care.
- Competitive Landscape Analysis: Alphatec faces intense competition from giants like Medtronic and Johnson & Johnson, relying on a limited number of suppliers, which may expose it to pricing pressures from hospital consolidations, while Inspire's dependence on its single product makes it vulnerable to shifts in market demand.
- Valuation Comparison: Alphatec has a forward P/E of 25.8x and a P/S ratio of 1.7x, while Inspire's forward P/E is significantly higher at 47.0x with a P/S ratio of 1.3x, highlighting notable differences in market valuations that investors should consider based on their risk preferences.
See More
Alphatec Faces Investor Lawsuit Investigation
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Alphatec Holdings, Inc. for potential violations of federal securities laws, which may impact investor rights.
- Earnings Miss: In its Q1 2026 financial results, Alphatec reported revenues below market expectations and lower than the previous year, leading to a stock price decline that reflects operational challenges.
- Outlook Downgrade: The company has reduced its 2026 EOS revenue outlook, citing installation timing issues and unfulfilled unit commitments, indicating difficulties in business execution.
- Investor Rights Protection: Bragar Eagel & Squire is gathering information from affected investors and offering legal consultation services to help them understand their rights and potential claims.
See More
Alphatec Holdings Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Alphatec and its executives have engaged in securities fraud or other unlawful business practices, prompting investors to reach out for more information, highlighting serious concerns over corporate governance.
- Earnings Miss: Alphatec's Q1 2026 financial results fell short of market expectations, with revenue declining compared to the prior year due to lower deliveries, indicating significant operational challenges facing the company.
- Guidance Downgrade: The company has lowered its full-year 2026 EOS revenue outlook, citing installation timing issues and unfulfilled unit commitments, suggesting increased pressure in market competition that could impact future financial performance.
- Stock Price Plunge: Following the earnings report, Alphatec's stock price dropped by $3.24, or 31.7%, closing at $6.99 per share on May 6, 2026, reflecting investor pessimism regarding the company's outlook.
See More
Alphatec Holdings Under Investigation for Investor Losses
- Revenue Decline: Alphatec Holdings reported a $3 million year-over-year decline in EOS revenue for Q1 2026, as system deliveries fell short of the previous year's figures, indicating increased pressure in market competition.
- Revised Revenue Guidance: The company lowered its 2026 EOS revenue forecast from approximately $85 million to $77 million, reflecting management's cautious outlook which may undermine investor confidence moving forward.
- Execution Flaw: CEO Patrick Miles identified installation timing as a challenge this quarter and labeled the unfulfilled unit commitments as an 'execution flaw,' which could negatively impact the company's market reputation and customer trust.
- Significant Stock Drop: Following these disclosures, Alphatec's stock price plummeted by approximately 32%, reflecting investor concerns about the company's future performance and potentially prompting more investors to seek legal remedies for their losses.
See More
U.S. Medical Devices ETF Underperforms
- ETF Decline: The iShares U.S. Medical Devices ETF fell approximately 2.4% in Tuesday afternoon trading, indicating overall weakness in the sector that may undermine investor confidence in medical devices.
- Weak Individual Stocks: Within the ETF, shares of Enovis dropped about 11.9%, while Alphatec Holdings fell by approximately 8.1%, with these significant declines likely negatively impacting the ETF's overall performance.
- Market Reaction Analysis: The poor performance of the medical device sector may reflect market concerns regarding the industry's future growth potential, particularly amid increasing economic uncertainty, prompting investors to reassess their portfolios.
- Investor Sentiment Shift: As the medical devices ETF underperforms, investors may shift towards stronger-performing ETFs, leading to capital outflows from the medical device sector and further exacerbating downward pressure on the industry.
See More
Alphatec Under Investigation as Shares Plunge 31.7%
- Investigation Launched: The Schall Law Firm has announced an investigation into Alphatec Holdings, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Disappointing Earnings: Alphatec's Q1 2026 financial results, released on May 5, revealed that revenue fell short of market expectations, with lower deliveries compared to the prior year, indicating operational challenges within the company.
- Revenue Outlook Downgraded: The company admitted to failing to fulfill committed unit quantities, leading to a lowered full-year 2026 revenue outlook, raising concerns about its future performance and exacerbating investor anxiety.
- Stock Price Volatility: Following the disappointing earnings and bleak outlook, Alphatec's shares plummeted by 31.7% on May 6, 2026, reflecting the market's strong reaction to the company's financial health, which could impact its ability to raise capital and investor confidence.
See More
Investment Analysis of Healthcare Device Players
- Alphatec Growth Momentum: Alphatec's revenue for FY 2025 reached approximately $764.2 million, reflecting a 25% increase, despite a net loss of about $143.4 million; however, its net margin improved from -26.5% to -18.8%, indicating growing market acceptance in spine surgery.
- Inspire's Profitability Improvement: Inspire Medical Systems achieved revenue of around $912 million in FY 2025, a 13.6% increase, and successfully transitioned to profitability with a net income of approximately $145.4 million, raising its net margin from 6.7% to 15.9%, solidifying its leadership in advanced respiratory care.
- Competitive Landscape Analysis: Alphatec faces intense competition from giants like Medtronic and Johnson & Johnson, relying on a limited number of suppliers, which may expose it to pricing pressures from hospital consolidations, while Inspire's dependence on its single product makes it vulnerable to shifts in market demand.
- Valuation Comparison: Alphatec has a forward P/E of 25.8x and a P/S ratio of 1.7x, while Inspire's forward P/E is significantly higher at 47.0x with a P/S ratio of 1.3x, highlighting notable differences in market valuations that investors should consider based on their risk preferences.
See More
Alphatec Faces Investor Lawsuit Investigation
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Alphatec Holdings, Inc. for potential violations of federal securities laws, which may impact investor rights.
- Earnings Miss: In its Q1 2026 financial results, Alphatec reported revenues below market expectations and lower than the previous year, leading to a stock price decline that reflects operational challenges.
- Outlook Downgrade: The company has reduced its 2026 EOS revenue outlook, citing installation timing issues and unfulfilled unit commitments, indicating difficulties in business execution.
- Investor Rights Protection: Bragar Eagel & Squire is gathering information from affected investors and offering legal consultation services to help them understand their rights and potential claims.
See More
Alphatec Holdings Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Alphatec and its executives have engaged in securities fraud or other unlawful business practices, prompting investors to reach out for more information, highlighting serious concerns over corporate governance.
- Earnings Miss: Alphatec's Q1 2026 financial results fell short of market expectations, with revenue declining compared to the prior year due to lower deliveries, indicating significant operational challenges facing the company.
- Guidance Downgrade: The company has lowered its full-year 2026 EOS revenue outlook, citing installation timing issues and unfulfilled unit commitments, suggesting increased pressure in market competition that could impact future financial performance.
- Stock Price Plunge: Following the earnings report, Alphatec's stock price dropped by $3.24, or 31.7%, closing at $6.99 per share on May 6, 2026, reflecting investor pessimism regarding the company's outlook.
See More
